The actively managed <font> HavRx Regulatory Catalyst Index </font> <font> tracks the performance of select companies which meet any of the following requirements: (1) pending new drug, biological agent, medical device, or diagnostic product applications at the FDA; (2) pending pivotal clinical trial results that are designed to support a new filing or resubmission for FDA marketing clearance; and (3) pending early stage clinical study results. Categories (1) and (2) will comprise two-third (67%) or greater of all index components while companies with pending early stage clinical trial results will comprise one-third (33%) or less of all index components. </font>
<font> </font>
<font> </font>
<font> <font> mikehavRx.com Index Updates </font> <font> is a premium service that provides investors with time-saving information and updates on unique global baskets of stocks that are organized and managed within the 18 HavRx Stock Indexes outlined below <font> that are being tracked at the Investars YOU website since June 2009. <font> Regulatory Catalyst Index Updates include daily updates on regular market trading days for active index components, watch list stocks, and binary event (FDA, clinical trials) summary information. </font> </font> </font> </font>
<font> </font>
<font> Regulatory Catalyst Index Update Statistics (as of 3/19/10 market close) </font>
- <font> 284 total entries to track select pending binary event data (FDA decisions, clinical trials) </font>
- <font> 186 companies tracked, including 95 active index components </font>
- <font> 143 companies under $10 per share, 107 companies under $5 per share </font>
<font> </font>
<font> mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and pending binary events such as FDA decisions and clinical trials, which are tracked in the actively managed Regulatory Catalyst Index. Please visit </font> <font> www.mikehavRx.com </font> <font> for more details on my new publishing company, website, and premium service. </font>